slides · global inventory
Callout
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 96,741
Current window 75,631-75,660
Pages 3,225
Rows per page 30
Component
75,631-75,660 of 96,741
347
The slide uses a combination of summary text and verbatim Q&A transcripts to highlight negative sentiment.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
348
The slide presents interview transcripts highlighting a lack of buzz at a major industry conference.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
349
The slide uses direct quotes to undermine the market potential and safety profile of the drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
350
The slide presents a Q&A format highlighting expert skepticism regarding the drug's safety profile and market relevance.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
351
The slide uses direct quotes to highlight physician skepticism and lack of awareness regarding the drug's trial flaws.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
352
The slide uses direct quotes to highlight the expert's negative sentiment toward the drug and the clinical trial methodology.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
353
The slide uses a Q&A format to highlight expert skepticism.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
354
The slide uses a Q&A format to highlight expert skepticism.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
355
The slide uses a Q&A format to build a case for market substitution risk.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
356
The slide uses a Q&A transcript format to highlight low adoption rates and physician skepticism.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
357
The slide uses a 'villain' narrative by framing a specific researcher (Jennifer Miller) and patient families as a 'cult' driving artificial demand.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
358
The slide uses a Q&A format to highlight skepticism among medical professionals regarding a drug's marketing presentation.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
359
The slide uses direct quotes to undermine the credibility of the company's sales representatives and the drug's market reception.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
360
The slide uses a summary headline followed by a verbatim quote with key phrases highlighted in yellow.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
361
The slide uses direct quotes from a pediatric endocrinologist to undermine the viability of a drug (Vykat/diazoxide).Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
362
The slide uses direct quotes from a pediatric endocrinologist to highlight concerns about the clinical management of diabetes risk associated with the drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
363
The slide highlights a discrepancy between the company's sales pitch and clinical best practices as perceived by an expert.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
365
The slide uses direct quotes from an endocrinologist to undermine the product's differentiation and pricing justification.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
366
The slide uses direct quotes to highlight a potential discrepancy between marketing claims and clinical reality.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
367
The slide highlights a direct contradiction between the company's marketing (Vykat) and expert clinical opinion.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
368
The slide highlights the physician's skepticism and the administrative hurdles faced with the drug Vykat.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
369
The slide highlights the endocrinologist's reluctance to prescribe the drug, noting that patient pressure was a primary driver for his involvement.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
370
The slide uses a Q&A format to expose that the drug's popularity is manufactured by advocacy groups rather than medical demand.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
371
The slide uses a Q&A transcript format to expose potential conflicts of interest between a company (Soleno) and a patient association.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
372
The slide uses a Q&A transcript format to highlight potential misinformation or manipulation by study investigators regarding drug efficacy timelines.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
373
The slide uses direct quotes to frame the expert's skepticism and clinical concerns about the drug's safety profile.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
374
The slide uses a Q&A transcript format to expose potential flaws in clinical trial methodology and physician sentiment.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
375
The slide uses highlighted text to emphasize key phrases from the expert's transcript.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
377
The slide uses a Q&A format to expose a gap in the company's support infrastructure.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
378
The slide uses a 'before-after' narrative structure to expose the contradiction between the physician's initial interest and his clinical assessment.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit